Answers are grounded in this paper and cite their sources.
Purpose FLASH radiotherapy (FLASH-RT) spares organs at risk (OARs) through the “FLASH effect” and is particularly advantageous under hypofractionation. Breast cancer is theoretically a favorable site for FLASH-RT implementation because the α/β ratio of breast tumors closely approximates that of late-reacting normal tissue. However, the normal-tissue sparing convolves two mechanisms: dose redistribution intrinsic to hypofractionation and the additional biological sparing of the FLASH effect, whose relative contributions across the dose spectrum remain unclear. Because clinical translation of FLASH hinges on the achievable degree of normal-tissue sparing, quantitative modeling grounded in existing experimental evidence is needed. We therefore aimed to disentangle and characterize these two components and assess how they combine in breast cancer. Methods Thirty clinically delivered breast VMAT plans (50 Gy/25 fractions) were retrospectively analyzed. Iso-effective hypofractionated regimens (1–5 fractions) preserving tumor biologically effective dose (BED) and relative spatial dose distribution were generated, and a voxel-based FLASH modifying factor (FMF) was applied to simulate the FLASH effect. After converting all regimens to a common conventional-fractionation basis, the sparing of dose-volume histogram (DVH) parameters, normal tissue complication probability (NTCP), and secondary cancer (SC) risk for the lungs, heart, and contralateral breast was quantified voxel-wise and decomposed into hypofractionation- and FLASH-driven components. Results Hypofractionated FLASH regimens consistently reduced OAR dose, NTCP and SC risk, with total sparing increasing as fraction number decreased and reaching largest under single fraction. Hypofractionation dominated low-dose metrics (lung V 5 , heart V 5 /V 10 ) and long-term SC risk (86–99% of the total Lifetime attributable risk reduction), where FLASH contributed only 1–2%. Conversely, the additional FLASH sparing increased with decreasing fraction number, contributing 11–12% for lung V 20 , up to 32% for lung V 30 , and 22% for contralateral breast D max . Under single-fraction delivery, FLASH accounted for 21% and 20% of the NTCP reduction for lungs and heart, respectively. Voxel-wise analysis confirmed spatially complementary mechanisms: hypofractionation spared low-dose regions most, and FLASH sparing was minimal at low doses and increased continuously toward high-dose regions. Conclusion In breast cancer, the additional FLASH effect specifically compensates for the limited high-dose-region sparing of hypofractionation, achieving comprehensive OAR protection across the dose spectrum through complementary, dose-dependent mechanisms. These findings support preferentially applying FLASH in ultra-hypofractionated breast RT.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: